Financial Model analyzing a Biopharmaceutical Company using a Risk-Adjusted NPV Valuation Methodology, designed to support strategic planning across R&D, clinical development, and commercialization. The model tracks costs related to drug development, clinical trials, regulatory milestones, and manufacturing, while projecting revenue from product launches, licensing deals, and partnerships. Whether developing a single asset or managing a broader pipeline, this model delivers the financial structure and insight needed to drive informed decisions and long-term growth.